Filana Therapeutics Inc (FLNA) Stock Price, Quote & News

Company Profile

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its na...

Industry: Biotechnology

Sector: Healthcare

Phone: 512 501 2444

Website: www.filanatx.com

Address:

6801 N. Capital of Texas Highway, Building 1, Austin, United States

2bitinvestor Apr. 25 at 1:17 PM

$FLNA .@Congratulations Are you seriously trying to pump this POS. There is no funding anymore. It is a scam.. If you were dumb enough to buy, you better get out while you have a chance for something.

0 · Reply

Dew8 Apr. 23 at 8:22 PM

$FLNA who else in over 10

1 · Reply

Congratulations Apr. 21 at 9:22 PM

$FLNA

1 · Reply

Congratulations Apr. 21 at 8:22 PM

$SAVAW Cassava Sciences $SAVA is now Filana Therapeutics $FLNA

0 · Reply

NotLong_NotShort Apr. 19 at 4:06 AM

$PBM just check the time of his posts on $AIXI, $WNW, and $SAVA, which becomes $FLNA . All of them turns into big losers.

1 · Reply

2bitinvestor Apr. 17 at 2:37 PM

$FLNA $1.00 by end of July IMO

0 · Reply

BioRich Apr. 17 at 4:23 AM

$FLNA

1 · Reply

JunkPost Apr. 16 at 6:43 PM

$FLNA FDA Clinical Hold Resolution (High Priority): The company is currently working to address an FDA clinical hold issued in December 2025. Any announcement regarding the submission of requested data or the lifting of this hold is the most significant near-term catalyst for the stock.

1 · Reply

JunkPost Apr. 16 at 6:42 PM

$FLNA No debt and below Cash Value. Grab it while you can. FDA news will be next

2 · Reply

Chrissytina Apr. 16 at 4:42 PM

$FLNA A little volume & play today…soon we’ll say 😂

1 · Reply

Cassava Sciences says US DOJ has closed investigation into company

Dec 24, 2025, 11:51 AM EST - 4 months ago

HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Dec 19, 2025, 11:31 AM EST - 4 months ago

FDA Puts Cassava's Simufilam Epilepsy Trial On Full Clinical Hold

Oct 22, 2025, 4:05 PM EDT - 6 months ago

Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 22, 2025, 8:00 AM EDT - 6 months ago

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

Aug 14, 2025, 7:30 AM EDT - 9 months ago

Cassava Reports Q2 2025 Financials Results and Provides Business Update

Aug 7, 2025, 7:30 AM EDT - 9 months ago

Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer

Aug 4, 2025, 7:30 AM EDT - 9 months ago

Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

Jun 30, 2025, 7:00 AM EDT - 10 months ago

Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting

May 1, 2025, 7:30 AM EDT - 1 year ago

Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC

Apr 21, 2025, 4:30 PM EDT - 1 year ago

Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development

Mar 26, 2025, 3:49 PM EDT - 1 year ago

Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug

Mar 25, 2025, 10:42 AM EDT - 1 year ago

Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop

Mar 25, 2025, 8:05 AM EDT - 1 year ago

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data

Mar 3, 2025, 7:30 AM EST - 1 year ago

Cassava Sciences Reports 2024 Financial Results and Provides Business Update

Feb 9, 2025, 10:45 AM EST - 1 year ago

Lead Plaintiff Deadline on February 10, 2025 for SAVA Investors - Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm

Feb 7, 2025, 12:08 PM EST - 1 year ago

SAVA Deadline: Rosen Law Firm Urges Cassava Sciences, Inc. (NASDAQ: SAVA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Feb 3, 2025, 5:45 AM EST - 1 year ago

Shareholders of Cassava Sciences, Inc. Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA

Jan 23, 2025, 2:47 PM EST - 1 year ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Jan 7, 2025, 4:30 PM EST - 1 year ago

Cassava Sciences Provides a Business Update

Dec 23, 2024, 5:45 AM EST - 1 year ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA

Dec 18, 2024, 10:53 AM EST - 1 year ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Dec 13, 2024, 1:16 PM EST - 1 year ago

Rosen Law Firm Urges Cassava Sciences, Inc. (NASDAQ: SAVA) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights

2bitinvestor Apr. 25 at 1:17 PM

0 · Reply

Dew8 Apr. 23 at 8:22 PM

$FLNA who else in over 10

1 · Reply

Congratulations Apr. 21 at 9:22 PM

$FLNA

1 · Reply

Congratulations Apr. 21 at 8:22 PM

$SAVAW Cassava Sciences $SAVA is now Filana Therapeutics $FLNA

0 · Reply

NotLong_NotShort Apr. 19 at 4:06 AM

$PBM just check the time of his posts on $AIXI, $WNW, and $SAVA, which becomes $FLNA . All of them turns into big losers.

1 · Reply

2bitinvestor Apr. 17 at 2:37 PM

$FLNA $1.00 by end of July IMO

0 · Reply

BioRich Apr. 17 at 4:23 AM

$FLNA

1 · Reply

JunkPost Apr. 16 at 6:43 PM

1 · Reply

JunkPost Apr. 16 at 6:42 PM

$FLNA No debt and below Cash Value. Grab it while you can. FDA news will be next

2 · Reply

Chrissytina Apr. 16 at 4:42 PM

$FLNA A little volume & play today…soon we’ll say 😂

1 · Reply

MaskMaker Apr. 16 at 1:37 AM

$AVXL $FLNA $GRRR $NXL $VTGN

1 · Reply

MaskMaker Apr. 16 at 12:57 AM

$AVXL $FLNA $GRRR $NXL $VTGN

0 · Reply

ZacksResearch Apr. 15 at 6:28 PM

$FLNA just dropped new seizure data — but there’s a catch ⚠️ Preclinical results published in Epilepsia show simufilam significantly slowed seizure progression in a severe TSC mouse model, with a clear dose-response relationship 📊. But the program is still under FDA clinical hold as the company works through additional data requests. See what Wall Street expects next 👉 https://www.zacks.com/stock/research/FLNA/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-37782&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_37782

0 · Reply

MaskMaker Apr. 15 at 5:59 PM

$FLNA $GRRR $NXL $VTGN

0 · Reply

focafoca99 Apr. 15 at 2:19 PM

$FLNA publication of preclinical simufilam data https://www.rapidticker.com/news/flna-filana-therapeutics-announces-publication-in-7431ae

0 · Reply

2bitinvestor Apr. 15 at 2:00 PM

$FLNA I hope those of you invested in this POS get some of your money back. My advice is get out while you can with what you can. Put it is something that has a chance. I am afraid this one has none with no source of funding.

0 · Reply

JunkPost Apr. 15 at 1:29 PM

$FLNA News is out, AUSTIN, Texas, April 15, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced publication in Epilepsia of preclinical data showing that simufilam attenuated seizure progression in a well-accepted mouse model of severe TSC-related epilepsy1. The results support the continued evaluation of simufilam for the treatment of TSC-related epilepsy, which affects approximately 45,000 people in the U.S.2,3. Simufilam is an oral small molecule intended to modulate filamin A protein.

1 · Reply

JunkPost Apr. 15 at 1:28 PM

$FLNA https://finance.yahoo.com/sectors/healthcare/articles/filana-therapeutics-announces-publication-epilepsia-120000533.html

0 · Reply

Bricktop200 Apr. 15 at 8:27 AM

$FLNA gold nuggets.

0 · Reply

MaskMaker Apr. 14 at 10:52 PM

$FLNA $GRRR $NXL $VTGN

0 · Reply

JunkPost Apr. 14 at 7:06 PM

$FLNA Huge upside if trials succeed One analyst target ~$8 vs ~$2 current price (~280% upside) If drug gets approval → potential multi-billion market opportunity 2. Strong cash (short-term stability) ~$95M cash, no debt Gives runway to continue trials without immediate dilution 3. Focused pipeline Pivot to TSC-related epilepsy may be more achievable than Alzheimer’s Early research shows seizure reduction in models

0 · Reply

iaconi Apr. 14 at 5:59 PM

$FLNA what we should expect from this near term? Only hope is a news with FDA

1 · Reply

Market Cap	80.19M
Revenue (ttm)	0.00
Net Income (ttm)	-90.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	349,500
Avg Vol	543,422
Day's Range	N/A - N/A
Shares Out	48.31M
Stochastic %K	28%
Beta	-0.67
Analysts	Strong Sell
Price Target	$8.00